Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 4, 28 April 2023
Open
Access | Article
2022 Looking Back at COVID-19 and Stem Cell Therapy
* Author to whom correspondence should be addressed.
Abstract
The global epidemic of Corona Virus Disease 2019 (COVID-19) has been raging since its outbreak in 2019, placing enormous strain on healthcare systems all over the world. The best course of action is to prevent COVID-19 in the future, despite the fact that its virological characteristics and pathogenesis have been largely understood. And all current treatment options probably include two types: one is active immunization and the other is passive immunization. Among them, passive immunity includes supportive therapy as well as neutralizing antibodies, and small molecule drugs and other treatments are used as supportive therapy, which only slows down the symptoms and prevents complications, and then waits for the body's immune system to heal itself. On the other hand, stem cell therapy is one type of active immunity. Typically, doctors use mesenchymal stem cells (MSC) to treat patients with severe or life-threatening disorders because of their potent immunomodulatory, anti-inflammatory, and tissue healing abilities. The remarkable developments in COVID-19 stem cell therapy during the past three years are outlined in this article, along with the current state of affairs. And it was found that although stem cell therapy has been successful in stages, it still has many limitations.
Keywords
SARS-CoV-2, Mesenchymal stem cells, COVID-19, Stem cell therapy
References
1. Esquivel, D. et al. Stem Cells Therapy as a Possible Therapeutic Option in Treating COVID-19 Patients. Stem Cell Reviews and Reports 17, 144-152. DOI: 10.1007/s12015-020-10017-6 (2021).
2. Pittenger, M. F. et al. Mesenchymal stem cell perspective: cell biology to clinical progress. npj Regenerative Medicine 4, 22. DOI: 10.1038/s41536-019-0083-6 (2019).
3. Ochani, R. et al. COVID-19 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management. Infez Med 29, 20-36 (2021).
4. Yuki, K., Fujiogi, M. & Koutsogiannaki, S. COVID-19 pathophysiology: A review. Clinical Immunology 215, 108427. DOI: https://doi.org/10.1016/j.clim.2020.108427 (2020).
5. Yang, L. et al. COVID-19: immunopathogenesis and Immunotherapeutics. Signal Transduction and Targeted Therapy 5, 128. DOI: 10.1038/s41392-020-00243-2 (2020).
6. von Stillfried, S. et al. First report from the German COVID-19 autopsy registry. The Lancet Regional Health - Europe 15, 100330. DOI: https://doi.org/10.1016/j.lanepe.2022.100330 (2022).
7. Rajarshi, K., Chatterjee, A. & Ray, S. Combating COVID-19 with mesenchymal stem cell therapy. Biotechnology Reports 26, e00467. DOI: https://doi.org/10.1016/j.btre.2020.e00467 (2020).
8. Choudhery, M. S. & Harris, D. T. Stem cell therapy for COVID-19: Possibilities and challenges. Cell Biology International 44, 2182-2191. DOI: https://doi.org/10.1002/cbin.11440 (2020).
9. Li, Z. et al. Stem cell therapy for COVID-19, ARDS and pulmonary fibrosis. Cell Proliferation 53, e12939. DOI: https://doi.org/10.1111/cpr.12939 (2020).
10. Song, N. et al. Mesenchymal stem cell immunomodulation: In pursuit of controlling COVID-19 related cytokine storm. Stem Cells 39, 707-722. DOI: 10.1002/stem.3354 (2021).
11. Jeyaraman, M. et al. Fostering mesenchymal stem cell therapy to halt cytokine storm in COVID-19. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1867, 166014. DOI: https://doi.org/10.1016/j.bbadis.2020.166014 (2021).
12. Shi, L. et al. Mesenchymal stem cell therapy for severe COVID-19. Signal Transduction and Targeted Therapy 6, 339. DOI: 10.1038/s41392-021-00754-6 (2021).
13. Shetty, R. et al. Stem cell therapy in coronavirus disease 2019: current evidence and future potential. Cytotherapy 23, 471-482. DOI: https://doi.org/10.1016/j.jcyt.2020.11.001 (2021).
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 2nd International Conference on Biological Engineering and Medical Science (ICBioMed 2022), Part II
- ISBN (Print)
- 978-1-915371-27-0
- ISBN (Online)
- 978-1-915371-28-7
- Published Date
- 28 April 2023
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/4/20220513
- Copyright
- 28 April 2023
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited